Vicapsys Life Sciences (VICP) 10-Q9 Sep 212020 Q2 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2020	Sep. 01, 2021
Document And Entity Information
Entity Registrant Name	Vicapsys Life Sciences, Inc.
Entity Central Index Key	0001468639
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		29,463,283
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current Assets:
Cash	$ 4,986	$ 264,166
Prepaid Expenses	3,883
Total Current Assets	8,869	264,166
Intangible asset, net of accumulated amortization of $73,966 and $58,241, respectively	418,548	434,273
Total Assets	427,417	698,439
Current Liabilities:
Accounts payable	477,812	396,482
Accounts payable, related parties	153,048
Accrued salaries, related party	79,858
Total Current Liabilities	710,718	396,482
Stockholders' Equity (Deficit):
Common Stock, par value $0.001; 300,000,000 shares authorized; 17,483,283 shares issued and outstanding	17,483	17,483
Common stock to be issued, par value $0.001; 651,281 shares outstanding	651	651
Additional paid-in capital	13,414,109	13,403,293
Accumulated deficit	(13,722,984)	(13,126,910)
Total Stockholders' Equity (Deficit)	(283,301)	301,957
Total Liabilities and Stockholders' Equity (Deficit)	427,417	698,439
Series A Preferred Stock [Member]
Stockholders' Equity (Deficit):
Preferred Stock Value	3,000	3,000
Total Stockholders' Equity (Deficit)	3,000	3,000
Series B Preferred Stock [Member]
Stockholders' Equity (Deficit):
Preferred Stock Value	4,440	4,440
Total Stockholders' Equity (Deficit)	$ 4,440	$ 4,440

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Intangible asset, net of accumulated amortization	$ 73,966	$ 58,241
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	17,483,283	17,483,283
Common stock, shares outstanding	17,483,283	17,483,283
Common stock to be issued, par value	$ 0.001	$ 0.001
Common stock to be issued, shares outstanding	651,281	651,281
Series A Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	3,000,000	3,000,000
Preferred stock, shares outstanding	3,000,000	3,000,000
Preferred stock liquidation preference value	$ 7,500,000	$ 7,500,000
Series B Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	4,440,000	4,440,000
Preferred stock, shares issued	4,440,000	4,440,000
Preferred stock, shares outstanding	4,440,000	4,440,000
Preferred stock liquidation preference value	$ 5,550,000	$ 5,550,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenues
Operating Expenses:
Personnel costs	93,653	35,898	192,731	173,316
Research and development expenses-related party			94,048
Professional fees	129,086	106,947	286,334	124,404
General and administrative expenses	8,876	8,497	22,961	17,217
Total operating expenses	231,615	151,342	596,074	314,937
Loss from continuing operations before income taxes	(231,615)	(151,342)	(596,074)	(314,937)
Income taxes
Loss from continuing operations	(231,615)	(151,342)	(596,074)	(314,937)
Loss from discontinued operations		(96,725)		(375,787)
Net Loss	$ (231,615)	$ (248,067)	$ (596,074)	$ (690,724)
Basic and diluted net loss per common share
Continuing operations	$ (0.01)	$ (0.02)	$ (0.03)	$ (0.03)
Discontinued operations		(0.01)		(0.03)
Earnings per share, basic and diluted	$ (0.01)	$ (0.03)	$ (0.03)	$ (0.06)
Basic and diluted weighted average common shares outstanding	17,483,283	10,050,133	17,483,283	9,850,133

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Common Stock to be Issued [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018	$ 3,000	$ 4,440	$ 9,650	$ 3,613	$ 11,282,359	$ (11,556,735)	$ (253,673)
Balance, shares at Dec. 31, 2018	3,000,000	4,440,000	9,650,133	3,612,880
Deemed dividend				$ 892	159,587	(160,479)
Deemed dividend, shares				891,551
Net loss						(442,657)	(442,657)
Balance at Mar. 31, 2019	$ 3,000	$ 4,440	$ 9,650	$ 4,505	11,441,946	(12,159,871)	(696,330)
Balance, shares at Mar. 31, 2019	3,000,000	4,440,000	9,650,133	4,504,431
Balance at Dec. 31, 2018	$ 3,000	$ 4,440	$ 9,650	$ 3,613	11,282,359	(11,556,735)	(253,673)
Balance, shares at Dec. 31, 2018	3,000,000	4,440,000	9,650,133	3,612,880
Net loss							(690,724)
Balance at Jun. 30, 2019	$ 3,000	$ 4,440	$ 11,930	$ 4,505	12,864,843	(12,407,938)	480,780
Balance, shares at Jun. 30, 2019	3,000,000	4,440,000	11,930,133	4,504,431
Balance at Mar. 31, 2019	$ 3,000	$ 4,440	$ 9,650	$ 4,505	11,441,946	(12,159,871)	(696,330)
Balance, shares at Mar. 31, 2019	3,000,000	4,440,000	9,650,133	4,504,431
Disposal of net liabilities to a related party					875,177		875,177
Shares issued in private placement			$ 2,280		547,720		550,000
Shares issued in private placement, shares			2,280,000
Net loss						(248,067)	(248,067)
Balance at Jun. 30, 2019	$ 3,000	$ 4,440	$ 11,930	$ 4,505	12,864,843	(12,407,938)	480,780
Balance, shares at Jun. 30, 2019	3,000,000	4,440,000	11,930,133	4,504,431
Balance at Dec. 31, 2019	$ 3,000	$ 4,440	$ 17,483	$ 651	13,403,293	(13,126,910)	301,957
Balance, shares at Dec. 31, 2019	3,000,000	4,440,000	17,483,283	651,281
Stock-based compensation expense					5,408		5,408
Net loss						(364,459)	(364,459)
Balance at Mar. 31, 2020	$ 3,000	$ 4,440	$ 17,483	$ 651	13,408,701	(13,491,369)	(57,094)
Balance, shares at Mar. 31, 2020	3,000,000	4,440,000	17,483,283	651,281
Balance at Dec. 31, 2019	$ 3,000	$ 4,440	$ 17,483	$ 651	13,403,293	(13,126,910)	301,957
Balance, shares at Dec. 31, 2019	3,000,000	4,440,000	17,483,283	651,281
Net loss							(596,074)
Balance at Jun. 30, 2020	$ 3,000	$ 4,440	$ 17,483	$ 651	13,414,109	(13,722,984)	(283,301)
Balance, shares at Jun. 30, 2020	3,000,000	4,440,000	17,483,283	651,281
Balance at Mar. 31, 2020	$ 3,000	$ 4,440	$ 17,483	$ 651	13,408,701	(13,491,369)	(57,094)
Balance, shares at Mar. 31, 2020	3,000,000	4,440,000	17,483,283	651,281
Stock-based compensation expense					5,408		5,408
Net loss						(231,615)	(231,615)
Balance at Jun. 30, 2020	$ 3,000	$ 4,440	$ 17,483	$ 651	$ 13,414,109	$ (13,722,984)	$ (283,301)
Balance, shares at Jun. 30, 2020	3,000,000	4,440,000	17,483,283	651,281

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash Flows from Operating Activities:
Net loss from continuing operations	$ (596,074)	$ (314,937)
Net loss from discontinued operations		(375,787)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization	15,725	15,725
Stock-based compensation	10,816
Changes in operating assets and liabilities:
Prepaid Expenses	(3,883)
Accounts payable	81,330	49,958
Accounts payable, related parties	153,048
Accrued liabilities	79,858
Net Cash Used in Operating Activities - continuing operations	(259,180)	(249,254)
Net Cash Used in Operating Activities - discontinued operations		(132,830)
Net Cash Used in Operating Activities	(259,180)	(382,084)
Cash Flows from Financing Activities:
Net Cash Provided By Financing Activities - continuing operations		550,000
Net Cash Provided By Financing Activities - discontinued operations		176,600
Net Cash Provided By Financing Activities		726,600
Net increase (decrease) in Cash	(259,180)	344,516
Cash, Beginning of period	264,166	86,330
Cash, End of period	4,986	430,846
Assets and liabilities transferred in AEI transaction:
Security deposits		(38,247)
Property and equipment, net		(175,818)
Accounts payable and accrued liabilities		150,395
Payable to related party		189,922
Advances payable, related parties		353,092
Accrued salaries, related parties		395,833
Increase (Decrease) in Operating Capital		$ 875,177

Organization

Organization	6 Months Ended
Organization	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	NOTE 1 - ORGANIZATION Business Vicapsys Life Sciences, Inc. (“VLS”) was incorporated in the State of Florida on July 8, 1997 under the name All Product Distribution Corp. On August 19, 1998, the Company changed its name to Phage Therapeutics International, Inc. On November 13, 2007, the Company changed its name to SSGI, Inc. On September 13, 2017, the Company changed its name to Vicapsys Life Sciences, Inc., effected a 1-for-100 reverse stock split of its outstanding common stock, increased the Company’s authorized capital stock to 300,000,000 shares of common stock, par value $0.001 per share, and 20,000,000 shares of “blank check” preferred stock, par value $0.001 per share. On December 22, 2017, pursuant to a Share Exchange Agreement (the “Exchange Agreement”) by and among VLS, Michael W. Yurkowsky, ViCapsys, Inc. ( “VI”) and the shareholders of VI, a private company, VI became a wholly owned subsidiary of VLS. We refer to VLS and VI together as the “Company”. VLS serves as the holding company for VI. Other than its interest in VI, VLS does not have any material assets or operations. On May 21, 2019, the Company closed an Investment and Restructuring Agreement (see Note 3). The Company’s strategy is to develop and commercialize, on a worldwide basis, various intellectual property rights (patents, patent applications, know how, etc.) relating to a series of encapsulated products that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immunoprotection around cells, tissues, organs and devices for therapeutic purposes. The product name VICAPSYN™ is the Company’s proprietary product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field.

Going Concern and Management's

Going Concern and Management's Plans	6 Months Ended
Going Concern and Management's Plans	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management's Plans	NOTE 2 – GOING CONCERN AND MANAGEMENT’S PLANS The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company experienced a net loss of $596,073 for the six months ended June 30, 2020, had a working capital deficit of $701,849 and an accumulated deficit of $13,722,983 as of June 30, 2020. These factors raise substantial doubt about the Company’s ability to continue as a going concern and to operate in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might result from this uncertainty. In March 2020, the World Health Organization declared the novel COVID-19 virus as a global pandemic. The COVID-19 outbreak in the United States has resulted in a significant impact to the Company’s ability to secure additional debt or equity funding to support operations in 2020. The Company has raised $365,000 (see Note 10) through August 2021 and management intends to raise additional funds in 2021 to support current operations and extend development of its product line. No assurance can be given that the Company will be successful in this effort. If the Company is unable to raise additional funds in 2021, it will be forced to severely curtail all operations and research and development activities.

Investment and Restructuring Ag

Investment and Restructuring Agreement	6 Months Ended
Investment and Restructuring Agreement	Jun. 30, 2020
Investments, All Other Investments [Abstract]
Investment and Restructuring Agreement	NOTE 3 – INVESTMENT AND RESTRUCTURING AGREEMENT On May 21, 2019 (the “Closing Date”), pursuant to that certain Investment and Restructuring Agreement, dated April 11, 2019 (the “IAR Agreement”), by and among the Company, YPH, LLC, (“YPH”), Stephen McCormack, the then Chief Executive Officer and a director of the Company, Steven Gorlin, then a director of the Company, Charles Farrahar, then the Chief Financial Officer of the Company, Athens Encapsulation Inc., (“AEI” and collectively with), Messrs. McCormack, Gorlin, Farrahar, the “AEI Parties”, and certain additional investors (collectively, the “Additional Investors”): ● Messrs. McCormack and Gorlin resigned from the Board of Directors of the Company and from all positions as officers or employees of the Company. ● Federico Pier was appointed as the Executive Chairman of the Board of Directors of the Company. Michael Yurkowsky and Frances Toneguzzo were appointed to the Board of Directors of the Company. Ms. Toneguzzo was appointed as the Chief Executive Officer of the Company. ● YPH and the Additional Investors (together, the “Investors”) purchased an aggregate of 3,980,000 shares of common stock of the Company at a purchase price of $0.25 per share and warrants to purchase 3,980,000 shares of common stock exercisable from the date of their respective investment dates (ranging from July 14, 2019 to September 9, 2019) (the “Investment Date”) until the third anniversary of the Investment Date for $0.50 per share. The Company received $971,500 net proceeds from the sale of the common stock and warrants. ● The Company assigned all of the Company’s right, title and interest in a Master Services Agreement, dated October 25, 2018 between the Company and Otsuka Pharmaceutical Factory, Inc. (“Otsuka”) related work orders with its customer, Otsuka, to AEI. ● VI assigned its lease to the Athens, Georgia Laboratory and office (the “Athens Facility”) to AEI. ● The Company contributed to AEI all physical assets located at the Athens Facility. These contributed assets did not include intellectual property related to the use of CXCL12, and the AEI Parties agreed that neither they nor any affiliated party will use CXCL12 or any analogues in any of its activities. The Company retained the right to use any of the “encapsulation technology” utilized or developed at the Athens Facility before the IAR Agreement was executed. ● AEI assumed certain liabilities of the Company, including, but not limited to, $189,922 owed by the Company to Aperisys, Inc., an aggregate of $353,092 in advances made by Messrs. Gorlin, Farrahar and McCormack to the Company an aggregate of $395,833 in accrued salaries owed by the Company to Messrs. McCormack and Farrahar; and an aggregate of $150,395 in trade payables attributable to the Athens Facility (the “AEI Assumed Liabilities”). ● AEI issued an aggregate of 1,600 shares of AEI common stock (the “AEI Common Stock”) to the officer and employees of AEI (the “AEI Shareholders”), representing 80% of the outstanding capital stock of AEI. The AEI Shareholders were Messrs. Gorlin, McCormack, and Farrahar, each of which is a current shareholder of the Company, and two of whom were former Directors of the Company. ● AEI issued 400 shares of its preferred stock (the “AEI Preferred Stock”), to the Company. Once AEI pays the AEI Assumed Liabilities noted above, the Certificate of Designation for the AEI Preferred Stock entitles the holder to receive all distributions made by AEI on any of its equity securities up to a total of $4,000,000 (the “AEI Preferred Payment”). Following the full payment of the AEI Preferred Payment, the AEI Preferred Stock shall automatically be converted into a number of shares of AEI Common Stock such that it is equal to 20% of all issued and outstanding AEI Common Stock at such time. ● Mr. McCormack and the Company amended Mr. McCormack’s original option agreement dated March 20, 2017, to (i) reduce the number of Mr. McCormack’s option shares from 1,440,000 to 600,000; and (ii) extend the exercise period of Mr. McCormack’s options from three (3) months to three (3) years following the Closing Date. Due to the related party nature of the transactions described above, the net liabilities transferred in the IAR Agreement of $875,177 were recorded as an increase to additional paid-in capital. Pursuant to the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification (“ASC”) 205-20 Presentation of Financial Statements: Discontinued Operations

Summary of Significant Accounti

Summary of Significant Accounting Principles	6 Months Ended
Summary of Significant Accounting Principles	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Principles	NOTE 4 – SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements in this report have been prepared by the Company without audit. In the opinion of management, all adjustments necessary to present the financial position, results of operations and cash flows for the stated periods have been made. Except as described below, these adjustments consist only of normal and recurring adjustments. Certain information and note disclosures normally included in the Company's consolidated annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with a reading of the Company's consolidated audited financial statements and notes thereto for the year ended December 31, 2019, filed in the Form 10. Interim results of operations for the three and six months ended June 30, 2020, and 2019, are not necessarily indicative of future results for the full year. The unaudited condensed consolidated financial statements of the Company include the consolidated accounts of VLS and its' wholly owned subsidiary VI. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates included in the financial statements, include useful the life of intangible assets, valuation allowance for deferred tax assets and non-cash equity transactions and stock-based compensation. Cash The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. The Company held no cash equivalents as of June 30, 2020, and December 31, 2019. Cash balances may, at certain times, exceed federally insured limits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail. Intangible Assets Costs of intangible assets are accounted for through the capitalization of those costs incurred in connection with developing or obtaining such assets. Capitalized costs are included in intangible assets in the unaudited condensed consolidated balance sheets. The Company’s intangible assets consist of costs incurred in connection with securing an Exclusive Patent License Agreement with The General Hospital Corporation, d/b/a Massachusetts General Hospital (“MGH”), as amended (the “License Agreement”). These costs are being amortized over the term of the License Agreement which is based on the remaining life of the related patents being licensed. The Company reviews these intangible assets for possible impairment when events or changes in circumstances indicate that the assets carrying amount may not be recoverable. In evaluating the future benefit of its intangible assets, management performs an analysis of the anticipated undiscounted future net cash flows of the intangible assets over the remaining estimated useful life. An impairment loss is recorded if the carrying value of the asset exceeds the expected future cash flows. Long-Lived Assets The Company reviews long-lived assets at least annually or when events or changes in circumstances reflect the fact that the recorded value may not be recoverable for impairment and recognizes impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying values. Discontinued Operations In accordance with ASC 205-20 Presentation of Financial Statements: Discontinued Operations In the period in which the component meets held-for-sale or discontinued operations criteria the major current assets, other assets, current liabilities, and noncurrent liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations, less applicable income taxes (benefit), shall be reported as components of net income (loss) separate from the net income (loss) of continuing operations. The Company disposed of a component of its business pursuant to the IAR Agreement (see Note 3) in May 2019, which met the definition of a discontinued operation. Accordingly, the operating results of the business transferred are reported as a loss from discontinued operations in the accompanying unaudited condensed consolidated statement of operations and statement of cash flows for the period ended June 30, 2019. For additional information, see Note 9- Discontinued Operations. Equity Method Investment The Company accounts for investments in which the Company owns more than 20% or has the ability to exercise significant influence of the investee, using the equity method in accordance with ASC Topic 323, Investments—Equity Method and Joint Ventures The amount of the adjustment is included in the determination of net income by the investor, and such amount reflects adjustments similar to those made in preparing consolidated statements including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between investor cost and underlying equity in net assets of the investee at the date of investment. The investment of an investor is also adjusted to reflect the investor’s share of changes in the investee’s capital. Dividends received from an investee reduce the carrying amount of the investment. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred which is other than temporary, and which should be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. In accordance with ASC 323-10-35-20 through 35-22, the investor ordinarily shall discontinue applying the equity method if the investment (and net advances) is reduced to zero and shall not provide for additional losses unless the investor has guaranteed obligations of the investee or is otherwise committed to provide further financial support for the investee. An investor shall, however, provide for additional losses if the imminent return to profitable operations by an investee appears to be assured. For example, a material, nonrecurring loss of an isolated nature may reduce an investment below zero even though the underlying profitable operating pattern of an investee is unimpaired. If the investee subsequently reports net income, the investor shall resume applying the equity method only after its share of that net income equals the share of net losses not recognized during the period the equity method was suspended. Equity and cost method investments are classified as investments. The Company periodically evaluates its equity and cost method investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded as an impairment loss in the accompanying consolidated statements of operations. The Company’s equity method investment consisted of equity owned in AEI which was given to the Company as part of an investment and restructuring agreement (see Note 3). In January 2021 (see Note 10), the Company sold its’ equity investment in AEI for $100,000. During the six months ended June 30, 2020 and 2019, the Company did not have any proportionate share of net income from AEI. Fair Value of Financial Instruments ASC 825, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of fair value information about financial instruments. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2020. The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, accounts payable and accrued liabilities, payables with related parties, approximate their fair values because of the short maturity of these instruments. Revenue Recognition Effective January 1, 2018, the Company adopted ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and all the related amendments. The Company elected to adopt this guidance using the modified retrospective method. The adoption of this guidance did not have a material effect on the Company’s consolidated financial position, results of operations or cash flows. The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company’s contracts with customers are generally on a contract and work order basis and represent obligations that are satisfied at a point in time, as defined in the new guidance, generally upon delivery or has services are provided. Stock Based Compensation Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation –Stock Compensation, Improvements to Employee Share-Based Payment Research and Development Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the six months ended June 30, 2020 and 2019, the Company incurred $94,048 and $0, respectively, in research and development expenses to a related party. Income Taxes The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes. Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment. ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. Interest and penalties are classified as a component of interest and other expenses. To date, the Company has not been assessed, nor paid, any interest or penalties. Uncertain tax positions are measured and recorded by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized. Earnings (Loss) Per Share The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of June 30, 2020 and 2019, the Company’s dilutive securities are convertible into approximately 17,688,006 and 19,841,156 shares of common stock, respectively. This amount is not included in the computation of dilutive loss per share because their impact is antidilutive. The following table represents the classes of dilutive securities as of June 30, 2020 and 2019: June 30, June 30, Common stock to be issued 651,281 4,504,431 Convertible preferred stock 10,440,000 10,440,000 Stock options 2,450,000 2,450,000 Warrants to purchase common stock 4,146,725 2,446,725 17,688,006 19,841,156 Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying unaudited condensed consolidated financial statements.

Intangible Assets

Intangible Assets	6 Months Ended
Intangible Assets	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	NOTE 5 – INTANGIBLE ASSETS The Company’s intangible assets consist of costs incurred in connection with the License Agreement with MGH, as amended (See Note 7). The consideration paid for the rights included in the License Agreement was in the form of common stock shares which resulted in MGH receiving approximately 20% of the total outstanding shares of common stock of VI. The estimated value of the common stock is being amortized over the term of the License Agreement which is based on the remaining life of the related patents being licensed which is approximately 16 years. The Company’s intangible assets consisted of the following at June 30, 2020, and December 31, 2019: June 30, December 31, 2019 Licensed patents $ 492,514 $ 492,514 Accumulated Amortization (73,966 ) (58,241 ) Balance $ 418,548 $ 434,273 The Company recognized $7,862 and $15,725 of amortization expense related to the License Agreement with MGH for the three and six months ended June 30, 2020, respectively. The Company recognized $7,821 and $15,642 of amortization expense related to the License Agreement with MGH for the three and six months ended June 30, 2019, respectively. Future expected amortization of intangible assets is as follows: Fiscal year ending December 31, 2020 (months remaining) $ 15,574 2021 31,299 2022 31,299 2023 31,299 2024 31,299 Thereafter 277,778 $ 418,548

Related Party Transactions

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 6 – RELATED PARTY TRANSACTIONS Consulting Agreement On June 21, 2019, the Company entered into a Consulting Agreement (the “Consulting Agreement”) with Mark Poznansky, MD, (the “Consultant”) a stockholder and former Director. The Company engaged the Consultant to render consulting services with respect to informing, guiding and supervising the development of antagonists to immune repellents or anti-fugetaxins for the treatment of cancer. The initial term of the Consulting Agreement is for one year (the “Initial Term”) and the Company agreed to pay the Consultant $3,000 per month commencing June 1, 2019, with the fee increasing to $6,000 per month commencing on the 1 st MGH License Agreement On May 8, 2013, VI and MGH a principal stockholder (see Note 5) entered into the License Agreement, pursuant to which MGH granted to the Company, in the field of coating and transplanting cells, tissues and devices for therapeutic purposes, on a worldwide basis: (i) an exclusive, royalty-bearing license under its rights in Patent Rights (as defined in the License Agreement) to make, use, sell, lease, import and transfer Products and Processes (each as defined in the License Agreement); (ii) a non-exclusive, sub-licensable (solely in the License Field and License Territory (each as defined in the License Agreement)) royalty-bearing license to Materials (as defined in the License Agreement) and to make, have made, use, have used, Materials for only the purpose of creating Products, the transfer of Products and to use, have used and transfer processes; (iii) the right to grant sublicenses subject to and in accordance with the terms of the License Agreement, and (iv) the nonexclusive right to use technological information (as defined in the License Agreement) disclosed by MGH to the Company under the License Agreement, all subject to and in accordance with the License Agreement (the “License”). As amended by the Seventh Amendment to the License Agreement on December 22, 2017, the License Agreement requires that VI satisfy the following requirements prior to the first sale of Products (“MGH License Milestones”), by certain dates which have passed. The table below lists the MGH Milestones and the Company’s progress in satisfying or negotiating the extension of each milestone: MILESTONE: STATUS: (i) Provide a detailed business and development plan. The Company has provided MGH with a completed Corporate pitch deck which outlines the Company’s business and development plans has been provided to MGH. (ii) Raise $2 million in a financing round. The Company has raised $1 million and is currently in the process of raising the second $1 million. The Company and MGH are currently negotiating extending this milestone. (iii) Initiate and finance research regarding the role of CXCL12 in minimizing fibrosis formation. Milestone completed. (iv) Initiate and finance research regarding the role of CXCL12 in beta cell function and differentiation. Dr. Poznansky’s lab was focusing on this as part of the academic project. The Company therefore made the strategic decision to fund another aspect of CXCL12 biology which focuses on the role of CXCL12 in wound healing. For the time being, the Company is excused from meeting this milestone as it has provided an alternative milestone as well as a justification for not pursuing this particular milestone. The Company and MGH have agreed to work together to restate the License Agreement, incorporating all the relevant provisions from the seven amendments and agreeing on a new set of milestones for future development. The License Agreement also requires VI to pay to MGH a one percent (1%) royalty rate on net sales related to the first license sub-field, which is the treatment of Type 1 Diabetes. Future sub-fields shall carry a reasonable royalty rate, consistent with industry standards, to be negotiated at the time the first such royalty payment shall become due with respect to the applicable Products and Processes (as defined in the License Agreement). The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal to or to exceed $100,000,000 in any calendar year and $4,000,000 within sixty (60) days after the first achievement of total net sales of Product or Process equal or exceed $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights. The License Agreement expires on the later of (i) the date on which all issued patents and filed patent applications within the Patent Rights have expired or been abandoned, and (ii) one (1) year after the last sale for which a royalty is due under the License Agreement. The License Agreement also grants MGH the right to terminate the License Agreement if VI fails to make any payment due under the License Agreement or defaults in the performance of any of its other obligations under the License Agreement, subject to certain notice and rights to cure set forth therein. MGH may also terminate the License Agreement immediately upon written notice to VI if VI: (i) shall make an assignment for the benefit of creditors; or (ii) or shall have a petition in bankruptcy filed for or against it that is not dismissed within sixty (60) days of filing. As of the date of this filing, this License Agreement remains active and the Company has not received any termination notice from MGH. VI may terminate the License Agreement prior to its expiration by giving ninety (90) days’ advance written notice to MGH, and upon such termination shall, subject to the terms of the License Agreement, immediately cease all use and sales of Products and Processes. The Company incurred research and development expenses to MGH of $0 and $94,048, respectively, during the three and six months ended June 30, 2020, all of which is in accounts payable as of June 30, 2020 on the unaudited condensed consolidated balance sheets. The Company did not incur any research and development expenses to MGH for the three and six months ended June 30, 2019. During the three and six months ended June 30, 2020 and 2019, there have not been any sales of Product or Process under this License Agreement. Investment and Restructuring Agreement (IAR Agreement) As discussed in Note 3, the Company transferred certain assets and liabilities to AEI, a company majority owned by three current stockholders of the Company, two of which were also former Directors and one was an officer of the Company. As a result of the IAR Agreement, the Company received 400 shares of preferred stock in AEI (See Note 10). Accounts Payable and Accrued Salaries The Company incurred director fees of $22,500 and $45,000 for the three and six months ended June 30, 2020, respectively, to Federico Pier, the Company’ Chairman of the Board, which is included in personnel costs on the unaudited condensed consolidated statements of operations. As of June 30, 2020, $30,000 of these director fees are included in accounts payable, related parties, on the unaudited condensed consolidated balance sheets. The Company incurred $15,000 in director fees to Federico Pier for the three and six months ended June 30, 2019. There were no amounts outstanding due related to these director fees as of December 31, 2019. The Company incurred consulting fees of $15,000 and $30,000 for the three and six months ended June 30, 2020, respectively, to Jeff Wright, the Company’s Chief Financial Officer, which is included in professional fees on the unaudited condensed consolidated statements of operations. As of June 30, 2020, $20,000 is included in accounts payable, related parties, on the unaudited condensed consolidated balance sheets. The Company did not incur any consulting fees to Jeff Wright for the three and six months ended June 30, 2019. In August 2020, Frances Tonneguzzo, the Company’s Chief Executive Officer (the “former CEO”) tendered her resignation as CEO (Note 10). For the three and six months ended June 30, 2020, the Company incurred expenses of $68,450 and $136,901 to the former CEO. As of June 30, 2020, $79,858 of unpaid salary to the former CEO is included in accrued salaries, related party, on the unaudited condensed consolidated balance sheets. For the three and six months ended June 30, 2019, the Company incurred expenses of $22,817 to the former CEO. All of the expenses to the former CEO are included in personnel costs on the unaudited condensed consolidated statements of operations.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 7– COMMITMENTS AND CONTINGENCIES Lease Agreements On March 1, 2014, the Company entered into a rental agreement with the Board of Regents of the University System of Georgia (“UGA”). As of July 1, 2016, the Company rented approximately 1,413 square feet for a monthly rent of $2,590 per month. Effective August 1, 2017, the Company rented approximately 2,771 square feet and the rent was increased to $5,542 per month and expiring July 1, 2019. The Company did not incur any rent expense under the rental agreement for the three and six months ended June 30, 2020. Rent expense under the rental agreement was $5,542 and $22,168, respectively, for the three and six months ended June 30, 2019, and is included in discontinued operations on the unaudited condensed consolidated statements of operations. The lease was assigned to AEI in May 2019. On June 3, 2017, the Company entered into an Equipment Lease Agreement (the “Lease Agreement”) for medical equipment with a cost of $76,600 (the equipment cost). Pursuant to the Lease Agreement, the Company paid a deposit of $32,705 and agreed to twenty-four (24) monthly payments (the term) of $1,756. The Company can acquire the equipment either a) after the first 6 monthly payments for the equipment cost minus the sum of the deposit and 70% of the monthly payments, or b) by paying seven (7) additional monthly payments at the end of the term. The Company did not incur any lease expense under the Lease Agreement for the three and six months ended June 30, 2020. Equipment lease expense under the Lease Agreement was $3,877 and $9,692 for the three and six months ended June 30, 2019 and is included in discontinued operations on the condensed consolidated statement of operations. The Company returned the equipment upon the expiration of the lease in May 2019. Legal Matters The Company is not aware of any material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest. MGH License Agreement As discussed in Note 7, the Company executed a License Agreement with MGH. The License Agreement also requires VI to pay to MGH a one percent (1%) royalty rate on net sales related to the first license sub-field, which is the treatment of Type 1 Diabetes. Future sub-fields shall carry a reasonable royalty rate, consistent with industry standards, to be negotiated at the time the first such royalty payment shall become due with respect to the applicable Products and Processes (as defined in the License Agreement). The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal or exceeding $100,000,000 in any calendar year and $4,000,000 within sixty (60) days after the first achievement of total net sales of Product or Process equal to or exceeding $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights. No expense reimbursements were paid to MGH during the three and six months ended June 30, 2020. Consulting Agreement On June 21, 2019, the Company entered into a Consulting Agreement (the “Consulting Agreement”) with C&H Capital, Inc. (the “Consultant”). The Company engaged the Consultant to render consulting services to facilitate long range strategic investor relations planning and other related services. The initial term of the Consulting Agreement is for one year (the “Initial Term”) and the Company agreed to pay the Consultant $3,500 on the last business day for each month of service. The Consulting Agreement was not renewed after the Initial Term due the Company’s working capital deficiencies. The Company incurred expenses of $10,500 and $21,000 for the three and six months ended June 30, 2020, respectively, related to the Consulting Agreement which is included in professional fees on the unaudited condensed consolidated statements of operations. As of June 30, 2020, $14,000 is included in accounts payable related to the Consulting Agreement. The Company did not incur any expenses related to the Consulting agreement with C&H Capital, Inc. for the three and six months ended June 30, 2019.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	6 Months Ended
Stockholders' Equity (Deficit)	Jun. 30, 2020
Equity [Abstract]
Stockholders' Equity (Deficit)	NOTE 8 – STOCKHOLDERS’ EQUITY (DEFICIT) Preferred Stock The Company has 20,000,000 authorized shares of preferred stock, $0.001 par value per share. Series A Preferred Stock On December 19, 2017, the Company amended its articles of incorporation by filing a certificate of designation with the Secretary of State of Florida therein designating a class of preferred stock as Series A Preferred Stock, $0.001 par value per share, consisting of 3 million (3,000,000) shares. Each holder of shares of Series A Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series A Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock. The holders of the Series A Preferred Stock shall vote together with the holders of the common stock of the Company as a single class and as single voting group upon all matters required to be submitted to a class or series vote pursuant to the protective provisions of the Certificate of Designation or under applicable law. In the event of liquidation, dissolution or winding up of the Corporation, either voluntarily or involuntarily, the holders of Series A Preferred Stock shall be entitled to receive, prior and in preference to any common stock holders, distribution of any surplus funds equal to the greater of (i) the sum of $1.67 per share or (ii) such amount per share as would have been payable had all shares been converted to common stock. The holder of Series A Preferred Stock may elect at any time to convert such shares into common stock of the Company. Each share of Series A Preferred Stock is convertible into shares of common stock at a conversion Rate of 2:1 (the “Series A Conversion Rate”). The Series A Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations. The shares of Series A Preferred Stock shall automatically convert into shares of common stock on February 12, 2021 (the one-year anniversary of the initial filing by the Company of a Form 10 filed with the Securities and Exchange Commission). The holders of the Series A Preferred Stock shall be entitled to participate with the holders of the common stock in any dividends paid or set aside for payment (other than dividends payable solely in shares of common stock) so that the holders of the Series A Preferred Stock shall receive with respect to each share of Series A Preferred Stock an amount equal to (x) the dividend payable with respect to each share of common stock multiplied by (y) the number of share of common stock into which such share of Series A Preferred Stock is convertible as of the record date for such dividend. Any such dividend shall be paid with respect to all then outstanding shares of common stock and Series A Preferred Stock on a pari passu basis and on as-converted basis. No dividends shall be paid on the common stock or the Series B Preferred Stock unless an equivalent dividend is paid with respect to the Series A Preferred Stock. In addition to any other rights and restrictions provided by applicable law, without first obtaining the affirmative vote or written consent of the holders of a majority of the then-outstanding shares of Series A Preferred Stock, the Company shall not amend or repeal any provision of, add any provision to, the Company’s Articles of Incorporation or the Series A Preferred Stock Certificate of Designation if such action would adversely alter or change the preferences, rights, privileges or power of, or restrictions provided for the benefit of, the Series A Preferred Stock. Unless otherwise prohibited by applicable law, the Board of Directors of the Company shall have the authority to repeal any provision of, or add any provision to, the Company’s Articles of Incorporation or Series A Preferred Stock Certificate of Designation if such action would not adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A Preferred Stock. As of June 30, 2020, and 2019, there were 3,000,000 shares of Series A Preferred Stock issued and outstanding. Series B Preferred Stock On December 19, 2017, the Company amended the articles of incorporation by filing a certificate of designation with the Secretary of State of Florida therein designating a class of preferred stock as Series B Preferred Stock, $0.001 par value per share, consisting of 4.44 million (4,440,000) shares (the “Series B Preferred Stock Certificate of Designation). Each holder of shares of Series B Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series B Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock. The holders of the Series B Preferred Stock shall vote together with the holders of the common stock of the Company as a single class and as single voting group upon all matters required to be submitted to a class or series vote pursuant to the protective provisions of the Series B Preferred Stock Certificate of Designation or under applicable law. In the event of liquidation, dissolution or winding up of the Corporation, either voluntarily or involuntarily, the holders of Series A Preferred Stock shall be entitled to receive, prior and in preference to any common stock holders, distribution of any surplus funds equal to the greater of : the sum of $0.83 per share or such amount per share as would have been payable had all shares been converted to common stock. The holder of Series B Preferred Stock may elect at any time to convert such sharers into common stock of the Company. Each share of Series B Preferred Stock is convertible into shares of common stock at a conversion rate of 1:1 (the “Series B Conversion Rate”). The Series B Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations. The shares of Series B Preferred Stock shall automatically convert into shares of common stock on February 12, 2021 (the one-year anniversary of the initial filing by the Company of a Form 10 filed with the Securities and Exchange Commission). The holders of the Series B Preferred Stock shall be entitled to participate with the holders of the common stock in any dividends paid or set aside for payment (other than dividends payable solely in shares of common stock) so that the holders of the Series B Preferred Stock shall receive with respect to each share of Series B Preferred Stock an amount equal to (x) the dividend payable with respect to each share of common stock multiplied by (y) the number of share of common stock into which such share of Series B Preferred Stock is convertible as of the record date for such dividend. Any such dividend shall be paid with respect to all then outstanding shares of common stock and Series B Preferred Stock on a pari passu basis and on as-converted basis. No dividends shall be paid on the common stock or the Series B Preferred Stock unless an equivalent dividend is paid with respect to the Series B Preferred Stock. In addition to any other rights and restrictions provided by applicable law, without first obtaining the affirmative vote or written consent of the holders of a majority of the then-outstanding shares of Series B Preferred Stock, the Company shall not amend or repeal any provision of, add any provision to, the Company’s Articles of Incorporation or the Series B Preferred Stock Certificate of Designation if such action would adversely alter or change the preferences, rights, privileges or power of, or restrictions provided for the benefit of, the Series B Preferred Stock. Unless otherwise prohibited by applicable law, the Board of Directors of the Company shall have the authority to repeal any provision of, or add any provision to, the Company’s Articles of Incorporation or Series B Preferred Stock Certificate of Designation if such action would not adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B Preferred Stock. As of June 30, 2020 and 2019, there were 4,440,000 shares of Series B Preferred Stock issued and outstanding. Common Stock The Company has 300,000,000 authorized shares of common stock, $0.001 par value per share. As of June 30, 2020, and December 31, 2019, there were 17,483,283 shares of common stock outstanding. Common Stock Issuance During the six months ended June 30, 2019, the Company sold 2,280,000 units, consisting of one share of common stock and one warrant to purchase a share of common stock (the “Units”). The Company sold 2,280,000 units at $0.25 to accredited investors. The Company received net proceeds of $550,000, net of $20,000 of issuance costs. The warrant has a three- year exercise term at a price per share of common stock of $0.50. The Company did not issue any shares of common stock during the six months ended June 30, 2020. Common Stock to be issued As of June 30, 2020 and 2019, there were 651,281 and 4,504,431, respectively, shares of common stock to be issued. As of June 30, 2020, 621,281 of the shares are to be issued under the IAR Agreements (see above), and 30,000 shares of common stock are to be issued to two initial shareholders of VI. During the period ended June 30, 2019, 891,551 shares of common stock were to be issued pursuant to a Stock Issuance and Release Agreement (“SRI Agreement”) executed by the Company to stockholders who purchased shares in 2018 at $1.85 per share for no consideration. The Company recorded a deemed dividend to stockholders of $160,479 for the shares to be issued under the SRI Agreements, at $0.18 per share, based upon the estimated underlying value of the common stock of $0.18 per share based upon recent Units sold by the Company. As of June 30, 2019, the remaining common stock to be issued consists of 3,612,880 shares to be issued to MGH pursuant to the License Agreement (see Notes 5, 6 and 7). Stock Options The following table summarizes activities related to stock options of the Company for the six months ended June 30, 2020: Number of Options Weighted-Average Exercise Price per Share Weighted-Average Remaining Life (Years) Outstanding at December 31, 2019 2,450,000 $ 0.57 8.20 Outstanding at June 30, 2020 2,450,000 $ 0.57 7.71 Exercisable at June 30,2020 2,116,667 $ 0.62 7.52 The Company did not grant any options to purchase shares of common stock during the three and six months ended June 30, 2020. The Company recorded stock compensation expense of $5,408 and $10,816 during the three and six months ended June 30, 2020, respectively. The Company did not record any stock-based compensation expense during the three and six months ended June 30, 2019, respectively. As of June 30, 2020, 333,333 options to purchase shares of common stock remain unvested and $43,261 of stock compensation expense remains unrecognized and will be expensed over a weighted average period of 2.50 years. Warrants The following table summarizes activities related to warrants of the Company for the six months ended June 30, 2020: Number of Warrants Weighted-Average Exercise Price per Share Weighted-Average Remaining Life (Years) Outstanding and exercisable at December 31, 2019 4,146,725 $ 0.53 2.50 Outstanding and exercisable at June 30, 2020 4,146,725 $ 0.53 2.01 The Company did not issue any warrants during the six- month period ended June 30,2020.

Discontinued Operations

Discontinued Operations	6 Months Ended
Discontinued Operations	Jun. 30, 2020
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	NOTE 9 – DISCONTINUED OPERATIONS In April 2019, the Company’s board of directors approved the IAR Agreement (See Note 3), whereby the Company, in effect transferred a segment of its business and the related assets and liabilities to AEI, a related party. The transaction was completed on May 21, 2019. ASC 205-20 “Discontinued Operations” establishes that the disposal or abandonment of a component of an entity or a group of components of an entity should be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. As a result, the component’s results of operations as of June 30, 2019 have been reclassified as discontinued operations on the condensed consolidated statements of operations. The results of operations of this component are separately reported as “discontinued operations” for the six months ended June 30, 2020. There have been no transactions between the Company and AEI since the IAR Agreement. A reconciliation of the major classes of line items constituting the loss from discontinued operations, net of income taxes as is presented in the unaudited condensed consolidated statements of operations for the three and six months ended June 30, 2020 and 2019 are summarized below: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Revenues $ — $ — $ — $ 50,000 Operating expenses: Personnel costs — 84,648 — 291,453 Travel expenses — 239 — 20,892 Laboratory expenses — 3,905 — 55,227 General and administrative expenses — 7,933 — 58,215 Total operating expenses — 96,725 — 425,787 Loss from discontinued operations $ — $ (96,725 ) $ — $ (375,787 ) There were no carrying amounts of major classes of assets and liabilities of the Company classified as discontinued operations in the unaudited condensed consolidated balance sheets at June 30, 2020 and December 31, 2019.

Subsequent Events

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 10 – SUBSEQUENT EVENTS In August 2020, Frances Tonneguzzo, the Company’s former CEO tendered her resignation as CEO. The resignation was not a result of any disagreement with the Company or its policies or practices. The total compensation incurred for 2020, prior to the receipt of the CEO’s resignation was $172,354, of which approximately $80,000 is included in accrued salaries, related party, as of June 30, 2020. In January 2021, the Company sold the 400 shares of AEI preferred stock, a related party, received as part of the IAR agreement (see Note 3) for $100,000. On February 12, 2021, the 3,000,000 shares of Series A Preferred Stock automatically converted into 6,000,000 shares of common stock, and the 4,440,000 shares of Series B Preferred Stock automatically converted into 4,440,000 shares of common stock. In June 2021, the Company entered into Security Purchase Agreements (“SPA’s) with select accredited investors in connection with a private offering by the Company to raise a maximum of $1,000,000 through the sale of common stock of the Company at $0.25 per share. The Company has sold 1,540,000 shares of common stock and received proceeds of $385,000 as of the date of these financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Principles (Policies)	6 Months Ended
Summary of Significant Accounting Principles (Policies)	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements in this report have been prepared by the Company without audit. In the opinion of management, all adjustments necessary to present the financial position, results of operations and cash flows for the stated periods have been made. Except as described below, these adjustments consist only of normal and recurring adjustments. Certain information and note disclosures normally included in the Company's consolidated annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with a reading of the Company's consolidated audited financial statements and notes thereto for the year ended December 31, 2019, filed in the Form 10. Interim results of operations for the three and six months ended June 30, 2020, and 2019, are not necessarily indicative of future results for the full year. The unaudited condensed consolidated financial statements of the Company include the consolidated accounts of VLS and its' wholly owned subsidiary VI. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates included in the financial statements, include useful the life of intangible assets, valuation allowance for deferred tax assets and non-cash equity transactions and stock-based compensation.
Cash	Cash The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. The Company held no cash equivalents as of June 30, 2020, and December 31, 2019. Cash balances may, at certain times, exceed federally insured limits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.
Intangible Assets	Intangible Assets Costs of intangible assets are accounted for through the capitalization of those costs incurred in connection with developing or obtaining such assets. Capitalized costs are included in intangible assets in the unaudited condensed consolidated balance sheets. The Company’s intangible assets consist of costs incurred in connection with securing an Exclusive Patent License Agreement with The General Hospital Corporation, d/b/a Massachusetts General Hospital (“MGH”), as amended (the “License Agreement”). These costs are being amortized over the term of the License Agreement which is based on the remaining life of the related patents being licensed. The Company reviews these intangible assets for possible impairment when events or changes in circumstances indicate that the assets carrying amount may not be recoverable. In evaluating the future benefit of its intangible assets, management performs an analysis of the anticipated undiscounted future net cash flows of the intangible assets over the remaining estimated useful life. An impairment loss is recorded if the carrying value of the asset exceeds the expected future cash flows.
Long-Lived Assets	Long-Lived Assets The Company reviews long-lived assets at least annually or when events or changes in circumstances reflect the fact that the recorded value may not be recoverable for impairment and recognizes impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying values.
Discontinued Operations	Discontinued Operations In accordance with ASC 205-20 Presentation of Financial Statements: Discontinued Operations In the period in which the component meets held-for-sale or discontinued operations criteria the major current assets, other assets, current liabilities, and noncurrent liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations, less applicable income taxes (benefit), shall be reported as components of net income (loss) separate from the net income (loss) of continuing operations. The Company disposed of a component of its business pursuant to the IAR Agreement (see Note 3) in May 2019, which met the definition of a discontinued operation. Accordingly, the operating results of the business transferred are reported as a loss from discontinued operations in the accompanying unaudited condensed consolidated statement of operations and statement of cash flows for the period ended June 30, 2019. For additional information, see Note 9- Discontinued Operations.
Equity Method Investment	Equity Method Investment The Company accounts for investments in which the Company owns more than 20% or has the ability to exercise significant influence of the investee, using the equity method in accordance with ASC Topic 323, Investments—Equity Method and Joint Ventures The amount of the adjustment is included in the determination of net income by the investor, and such amount reflects adjustments similar to those made in preparing consolidated statements including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between investor cost and underlying equity in net assets of the investee at the date of investment. The investment of an investor is also adjusted to reflect the investor’s share of changes in the investee’s capital. Dividends received from an investee reduce the carrying amount of the investment. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred which is other than temporary, and which should be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. In accordance with ASC 323-10-35-20 through 35-22, the investor ordinarily shall discontinue applying the equity method if the investment (and net advances) is reduced to zero and shall not provide for additional losses unless the investor has guaranteed obligations of the investee or is otherwise committed to provide further financial support for the investee. An investor shall, however, provide for additional losses if the imminent return to profitable operations by an investee appears to be assured. For example, a material, nonrecurring loss of an isolated nature may reduce an investment below zero even though the underlying profitable operating pattern of an investee is unimpaired. If the investee subsequently reports net income, the investor shall resume applying the equity method only after its share of that net income equals the share of net losses not recognized during the period the equity method was suspended. Equity and cost method investments are classified as investments. The Company periodically evaluates its equity and cost method investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded as an impairment loss in the accompanying consolidated statements of operations. The Company’s equity method investment consisted of equity owned in AEI which was given to the Company as part of an investment and restructuring agreement (see Note 3). In January 2021 (see Note 10), the Company sold its’ equity investment in AEI for $100,000. During the six months ended June 30, 2020 and 2019, the Company did not have any proportionate share of net income from AEI.
Fair Value of Financial Instruments	Fair Value of Financial Instruments ASC 825, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of fair value information about financial instruments. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2020. The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, accounts payable and accrued liabilities, payables with related parties, approximate their fair values because of the short maturity of these instruments.
Revenue Recognition	Revenue Recognition Effective January 1, 2018, the Company adopted ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and all the related amendments. The Company elected to adopt this guidance using the modified retrospective method. The adoption of this guidance did not have a material effect on the Company’s consolidated financial position, results of operations or cash flows. The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company’s contracts with customers are generally on a contract and work order basis and represent obligations that are satisfied at a point in time, as defined in the new guidance, generally upon delivery or has services are provided.
Stock Based Compensation	Stock Based Compensation Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation –Stock Compensation, Improvements to Employee Share-Based Payment
Research and Development	Research and Development Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the six months ended June 30, 2020 and 2019, the Company incurred $94,048 and $0, respectively, in research and development expenses to a related party.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes. Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment. ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. Interest and penalties are classified as a component of interest and other expenses. To date, the Company has not been assessed, nor paid, any interest or penalties. Uncertain tax positions are measured and recorded by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.
Earnings (Loss) Per Share	Earnings (Loss) Per Share The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of June 30, 2020 and 2019, the Company’s dilutive securities are convertible into approximately 17,688,006 and 19,841,156 shares of common stock, respectively. This amount is not included in the computation of dilutive loss per share because their impact is antidilutive. The following table represents the classes of dilutive securities as of June 30, 2020 and 2019: June 30, June 30, Common stock to be issued 651,281 4,504,431 Convertible preferred stock 10,440,000 10,440,000 Stock options 2,450,000 2,450,000 Warrants to purchase common stock 4,146,725 2,446,725 17,688,006 19,841,156
Recent Accounting Pronouncements	Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying unaudited condensed consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Principles (Tables)	6 Months Ended
Summary of Significant Accounting Principles (Tables)	Jun. 30, 2020
Accounting Policies [Abstract]
Schedule of Antidilutive Securities of Earnings Per Share	The following table represents the classes of dilutive securities as of June 30, 2020 and 2019: June 30, June 30, Common stock to be issued 651,281 4,504,431 Convertible preferred stock 10,440,000 10,440,000 Stock options 2,450,000 2,450,000 Warrants to purchase common stock 4,146,725 2,446,725 17,688,006 19,841,156

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
Intangible Assets (Tables)	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	The Company’s intangible assets consisted of the following at June 30, 2020, and December 31, 2019: June 30, December 31, 2019 Licensed patents $ 492,514 $ 492,514 Accumulated Amortization (73,966 ) (58,241 ) Balance $ 418,548 $ 434,273
Schedule of Future Amortization of Intangible Assets	Future expected amortization of intangible assets is as follows: Fiscal year ending December 31, 2020 (months remaining) $ 15,574 2021 31,299 2022 31,299 2023 31,299 2024 31,299 Thereafter 277,778 $ 418,548

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	6 Months Ended
Stockholders' Equity (Deficit) (Tables)	Jun. 30, 2020
Equity [Abstract]
Schedule of Stock Options Activity	The following table summarizes activities related to stock options of the Company for the six months ended June 30, 2020: Number of Options Weighted-Average Exercise Price per Share Weighted-Average Remaining Life (Years) Outstanding at December 31, 2019 2,450,000 $ 0.57 8.20 Outstanding at June 30, 2020 2,450,000 $ 0.57 7.71 Exercisable at June 30,2020 2,116,667 $ 0.62 7.52
Schedule of Warrants Activity	The following table summarizes activities related to warrants of the Company for the six months ended June 30, 2020: Number of Warrants Weighted-Average Exercise Price per Share Weighted-Average Remaining Life (Years) Outstanding and exercisable at December 31, 2019 4,146,725 $ 0.53 2.50 Outstanding and exercisable at June 30, 2020 4,146,725 $ 0.53 2.01

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
Discontinued Operations (Tables)	Jun. 30, 2020
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Loss from Discontinued Operations	A reconciliation of the major classes of line items constituting the loss from discontinued operations, net of income taxes as is presented in the unaudited condensed consolidated statements of operations for the three and six months ended June 30, 2020 and 2019 are summarized below: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Revenues $ — $ — $ — $ 50,000 Operating expenses: Personnel costs — 84,648 — 291,453 Travel expenses — 239 — 20,892 Laboratory expenses — 3,905 — 55,227 General and administrative expenses — 7,933 — 58,215 Total operating expenses — 96,725 — 425,787 Loss from discontinued operations $ — $ (96,725 ) $ — $ (375,787 )

Organization (Details Narrative

Organization (Details Narrative) - $ / shares	Sep. 13, 2017	Jun. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reverse stock split	1-for-100 reverse stock split
Common stock, shares authorized	300,000,000	300,000,000	300,000,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000	20,000,000
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001

Going Concern and Management'_2

Going Concern and Management's Plans (Details Narrative) - USD ($)	Aug. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Net loss		$ (231,615)	$ (364,459)	$ (248,067)	$ (442,657)	$ (596,074)	$ (690,724)
Working capital		(701,849)				(701,849)
Accumulated deficit		$ (13,722,984)				(13,722,984)		$ (13,126,910)
Proceed from sale of common stock						$ 550,000
Subsequent Event [Member]
Proceed from sale of common stock	$ 365,000

Investment and Restructuring _2

Investment and Restructuring Agreement (Details Narrative) - USD ($)	May 21, 2019	Mar. 20, 2017	Mar. 19, 2017	Jun. 30, 2020
Proceeds from sale of common stock				$ 550,000
AEI Preferred Stock [Member]
Shares of common stock	400
Preferred payment	$ 4,000,000
Issued and outstanding common stock percentage	20.00%
Messrs.Gorlin, Farrahar and McCormack [Member]
Advance to affiliates	$ 353,092
Accrued salaries	$ 395,833
AEI Shareholders [Member]
Shares of common stock	1,600
Outstanding capital stock percentage	80.00%
YPH, LLC [Member] \| Investors [Member]
Shares of common stock	3,980,000
Share price per share	$ 0.25
Shares of common stock exercisable	3,980,000
Proceeds from sale of common stock	$ 971,500
YPH, LLC [Member] \| Investors [Member] \| Until Third Anniversary [Member]
Share price per share	$ 0.50
Aperisys, Inc [Member]
Due to related parties	$ 189,922
Athens Encapsulation Inc [Member]
Trade payables	$ 150,395
Mr. McCormack [Member]
Shares of common stock		600,000	1,440,000

Summary of Significant Accoun_4

Summary of Significant Accounting Principles (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2021	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Accounting Policies [Abstract]
Cash equivalents
Investment percentage		20.00%		20.00%
Proceed from issuance of equity	$ 100,000
Research and development expenses				$ 94,048
Antidilutive securities				17,688,006	19,841,156

Summary of Significant Accoun_5

Summary of Significant Accounting Principles - Schedule of Antidilutive Securities of Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	17,688,006	19,841,156
Common Stock to be Issued [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	651,281	4,504,431
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	10,440,000	10,440,000
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	2,450,000	2,450,000
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	4,146,725	2,446,725

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - License Agreement [Member] - Massachusetts General Hospital [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Finite-Lived Intangible Assets [Line Items]
Percentage of outstanding common shares			20.00%
Intangible assets remaining amortized period			16 years
Amortization expenses	$ 7,862	$ 7,821	$ 15,725	$ 15,642

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Licensed patents	$ 492,514	$ 492,514
Accumulated Amortization	(73,966)	(58,241)
Balance	$ 418,548	$ 434,273

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Future Amortization of Intangible Assets (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
2020 (months remaining)	$ 15,574
2021	31,299
2022	31,299
2023	31,299
2024	31,299
Thereafter	277,778
Intangible Assets, Net	$ 418,548	$ 434,273

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jun. 21, 2019	Dec. 22, 2017	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Related Party Transaction [Line Items]
Accounts payable			$ 153,048		$ 153,048
Research and development expenses					94,048
Professional fees			129,086	106,947	286,334	124,404
Incurred expenses			68,450		68,450
Accrued salaries			79,858		79,858
Federico Pier [Member]
Related Party Transaction [Line Items]
Accounts payable			30,000		30,000
Professional fees			22,500	15,000	45,000	15,000
Jeff Wright [Member]
Related Party Transaction [Line Items]
Accounts payable			20,000		20,000
Professional fees			15,000		30,000
Former CEO [Member]
Related Party Transaction [Line Items]
Incurred expenses			136,901	22,817	136,901	22,817
CEO [Member]
Related Party Transaction [Line Items]
Accrued salaries			79,858		79,858
Massachusetts General Hospital [Member]
Related Party Transaction [Line Items]
Research and development expenses			0		94,048
Consulting Agreement [Member]
Related Party Transaction [Line Items]
Related party expenses			9,000		18,000
Accounts payable			$ 9,000		9,000
Consulting Agreement [Member] \| Consultant [Member] \| Initial Term [Member]
Related Party Transaction [Line Items]
Payment to related party	$ 3,000
Fees increasing	6,000
Fundraising amount	$ 5,000,000
License Agreement [Member]
Related Party Transaction [Line Items]
Fundraising amount		$ 2,000,000
Fundraising description		The Company has raised $1 million and is currently in the process of raising the second $1 million. The Company and MGH are currently negotiating extending this milestone.
Royalty rate on sales		1.00%
Related parties, description		The License Agreement additionally requires VI to pay to MGH a $1.0 million "success payment" within 60 days after the first achievement of total net sales of Product or Process equal to or to exceed $100,000,000 in any calendar year and $4,000,000 within sixty (60) days after the first achievement of total net sales of product or process equal or exceed $250,000,000 in any calendar year. The Company is also required to reimburse MGH's expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights.
License Agreement [Member] \| Massachusetts General Hospital [Member]
Related Party Transaction [Line Items]
Payment to related party					$ 1,000,000
IAR agreement [Member]
Related Party Transaction [Line Items]
Number of common stock					400

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	Jun. 21, 2019USD ($)	Aug. 01, 2017USD ($)ft²	Jun. 03, 2017USD ($)	Jul. 01, 2016USD ($)ft²	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)
Loss Contingencies [Line Items]
Monthly rent						$ 5,542		$ 22,168
Professional fees					$ 129,086	106,947	$ 286,334	124,404
Accounts payable					477,812		477,812		$ 396,482
Rental Agreement [Member]
Loss Contingencies [Line Items]
Area of land \| ft²		2,771		1,413
Monthly rent		$ 5,542		$ 2,590
Lease expiration		Jul. 1, 2019
Equipment Lease Agreement [Member]
Loss Contingencies [Line Items]
Monthly rent			$ 1,756
Medical equipment			76,600
Deposit			$ 32,705
Lease term			24 months
Percentage of monthly rent			70.00%
Equipment lease expense						$ 3,877		$ 9,692
License Agreement [Member] \| Massachusetts General Hospital [Member]
Loss Contingencies [Line Items]
Percentage for royalty							1.00%
Payment for related party							$ 1,000,000
License agreement, description							The License Agreement additionally requires VI to pay to MGH a $1.0 million "success payment" within 60 days after the first achievement of total net sales of Product or Process equal or exceeding $100,000,000 in any calendar year and $4,000,000 within sixty (60) days after the first achievement of total net sales of Product or Process equal to or exceeding $250,000,000 in any calendar year.
Consulting Agreement [Member] \| C&H Capital, Inc [Member]
Loss Contingencies [Line Items]
Payment for related party	$ 3,500
Agreement term	1 year
Professional fees					10,500		$ 21,000
Accounts payable					$ 14,000		$ 14,000

Stockholders' Equity (Deficit_2

Stockholders' Equity (Deficit) (Details Narrative) - USD ($)	Dec. 19, 2017	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Sep. 13, 2017
Class of Stock [Line Items]
Preferred stock, shares authorized		20,000,000		20,000,000		20,000,000		20,000,000
Preferred stock par value		$ 0.001		$ 0.001		$ 0.001		$ 0.001
Common stock par value		$ 0.001		$ 0.001		$ 0.001		$ 0.001
Common stock, shares authorized		300,000,000		300,000,000		300,000,000		300,000,000
Common stock, shares issued		17,483,283		17,483,283		17,483,283
Common stock, shares outstanding		17,483,283		17,483,283		17,483,283
Proceed from issuance of shares				$ 550,000
Issuance cost				$ 20,000
Common stock to be issued, shares outstanding		651,281	4,504,431	651,281	4,504,431	651,281
Private Placement [Member]
Class of Stock [Line Items]
Shares issued in private placement, shares				2,280,000
Sale of stock price per shares		$ .25		$ .25
Stock Options [Member]
Class of Stock [Line Items]
Stock compensation expense		$ 5,408		$ 10,816
Number of option to purchase				333,333
Stock compensation expense remains unrecognized		$ 43,261		$ 43,261
Weighted average period				2 years 6 months
Two Initial Shareholders [Member]
Class of Stock [Line Items]
Common stock to be issued, shares outstanding		30,000		30,000
IAR Agreements [Member]
Class of Stock [Line Items]
Common stock to be issued, shares outstanding		621,281		621,281
Stock Issuance and Release Agreements [Member]
Class of Stock [Line Items]
Sale of stock price per shares			$ 0.18		$ 0.18
Number of common stock to be issued					891,551
Shares issued price per share			$ 0.18		$ 0.18		$ 1.85
Deemed dividend					$ 160,479
License Agreement [Member] \| Massachusetts General Hospital [Member]
Class of Stock [Line Items]
Number of common stock to be issued					3,612,880
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	3,000,000	3,000,000		3,000,000		3,000,000
Preferred stock par value	$ 0.001	$ 0.001		$ 0.001		$ 0.001
Preferred stock voting rights	Each holder of shares of Series A Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series A Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock.
Preferred stock converted per shares	167.00%
Preferred stock conversion, description	Each share of Series A Preferred Stock is convertible into shares of common stock at a conversion Rate of 2:1 (the "Series A Conversion Rate").
Preferred stock, shares issued		3,000,000		3,000,000		3,000,000
Preferred stock, shares outstanding		3,000,000		3,000,000		3,000,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	4,440,000	4,440,000		4,440,000		4,440,000
Preferred stock par value	$ 0.001	$ 0.001		$ 0.001		$ 0.001
Preferred stock voting rights	Each holder of shares of Series B Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series B Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock.
Preferred stock converted per shares	83.00%
Preferred stock conversion, description	Each share of Series B Preferred Stock is convertible into shares of common stock at a conversion rate of 2:1 (the "Series B Conversion Rate").
Preferred stock, shares issued		4,440,000		4,440,000		4,440,000
Preferred stock, shares outstanding		4,440,000		4,440,000		4,440,000

Stockholders' Equity (Deficit_3

Stockholders' Equity (Deficit) - Schedule of Stock Options Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Equity [Abstract]
Number of Options, Outstanding	2,450,000	2,450,000
Number of Options, Exercisable	2,116,667
Weighted-Average Exercise Price per Share, Beginning Balance	$ 0.57	$ 0.57
Weighted-Average Exercise Price per Share, Exercisable	$ 0.62
Weighted-Average Remaining Life (Years)	7 years 8 months 16 days	8 years 2 months 12 days
Weighted-Average Remaining Life (Years), Exercisable	7 years 6 months 7 days

Stockholders' Equity (Deficit_4

Stockholders' Equity (Deficit) - Schedule of Warrants Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Equity [Abstract]
Number of Warrants, Outstanding and exercisable	4,146,725	4,146,725
Weighted-Average Exercise Price per Share	$ 0.53	$ 0.53
Weighted-Average Remaining Life (Years)	2 years 4 days	2 years 6 months

Discontinued Operations - Sched

Discontinued Operations - Schedule of Loss from Discontinued Operations (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Discontinued Operations and Disposal Groups [Abstract]
Revenues				$ 50,000
Personnel costs		84,648		291,453
Travel expenses		239		20,892
Laboratory expenses		3,905		55,227
General and administrative expenses		7,933		58,215
Total operating expenses		96,725		425,787
Loss from discontinued operations		$ (96,725)		$ (375,787)

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Aug. 31, 2021	Jun. 30, 2021	Feb. 12, 2021	Jan. 31, 2021	Jun. 30, 2019	Jun. 30, 2020	Aug. 31, 2020	Dec. 31, 2019
Accrued salary						$ 79,858
Proceeds from sale of common stock						$ 550,000
Common Stock [Member]
Shares of common stock					2,280,000
Private Placement [Member]
Shares of common stock						2,280,000
Sale of stock price per share						$ .25
IAR agreement [Member]
Shares of common stock						400
Subsequent Event [Member]
Proceeds from sale of common stock	$ 365,000
Subsequent Event [Member] \| Common Stock [Member]
Proceeds from sale of common stock		$ 1,540,000
Subsequent Event [Member] \| Series A Preferred Stock [Member]
Shares of common stock			3,000,000
Subsequent Event [Member] \| Series A Preferred Stock [Member] \| Common Stock [Member]
Shares of common stock			6,000,000
Subsequent Event [Member] \| Series B Preferred Stock [Member]
Shares of common stock			4,440,000
Subsequent Event [Member] \| Series B Preferred Stock [Member] \| Common Stock [Member]
Shares of common stock			4,440,000
Subsequent Event [Member] \| IAR agreement [Member]
Number of shares sold				400
Proceeds from sale of common stock				$ 100,000
Subsequent Event [Member] \| Security Purchase Agreements [Member] \| Private Placement [Member]
Proceeds from sale of common stock		$ 385,000
Sale of stock price per share		$ .25
Subsequent Event [Member] \| Security Purchase Agreements [Member] \| Private Placement [Member] \| Maximum [Member]
Proceeds from sale of common stock		$ 1,000,000
Subsequent Event [Member] \| Frances Tonneguzzo [Member]
Compensation yet to pay							$ 172,354
Accrued salary							$ 80,000